Inventisbio Co.,Ltd. (688382.SH) has issued an annual performance forecast for 2025, anticipating a net loss attributable to owners of the parent company of 292 million yuan for the year. The company's performance change in 2025 is primarily influenced by the combined effects of R&D investment intensity and revenue composition. With the solid advancement of its R&D pipeline, several core clinical projects have entered critical stages and achieved positive progress, maintaining R&D expenditures at a high level: the oral selective estrogen receptor degrader (SERD) D0502 is currently undergoing a pivotal Phase III clinical trial in China for second-line treatment; the TYK2 inhibitor D-2570 has initiated clinical exploration in multiple autoimmune disease areas, including an ongoing Phase II trial for ulcerative colitis in China, a pivotal Phase III trial for psoriasis, and a Phase I trial in the United States; the URAT1 inhibitor D-0120 completed follow-up during the reporting period for its combination therapy Phase II trial in the U.S., with all research work expected to be finalized in the first quarter of 2026. In 2025, the company also achieved key progress in the translation of its preclinical pipeline, with two innovative preclinical candidate drugs, the WRN inhibitor YF087 and the KIF18A inhibitor YF550, demonstrating excellent anti-tumor potential in multiple preclinical studies; these are currently undergoing IND-enabling studies to prepare for subsequent entry into clinical stages. Simultaneously, the company continues to invest in early-stage research and development, including the development of other candidate drugs, the construction of innovative technology platforms, and early-stage drug discovery, to accumulate momentum for long-term growth.
Comments